Biologics Market Projected to Reach USD 1.28 Trillion by 2035; Japan Segments Grow

The global biologics market was valued at USD 519.72 billion in 2025 and is projected to reach USD 1,283.29 billion by 2035, growing at a CAGR of 9.46% during 2026–2035. The U.S. biologics market was valued at USD 233.87 billion in 2025 and is expected to reach USD 577.48 billion by 2035.

Biologics, including vaccines, cell therapy/gene therapy, recombinant proteins, RNA-based therapeutics, and monoclonal antibodies, have proven to be highly successful in treating a variety of chronic illnesses, including diabetes, cancer, and autoimmune diseases. By 2030, there will likely be 22 million cancer cases worldwide; over 530 million people worldwide suffer with diabetes; and cardiovascular disease remains the primary cause of death worldwide.

By source, mammalian cells dominated the market with a 65% share in 2025, supported by their capability to create complex, human-type proteins. Microbial cells are emerging as the fastest-growing segment through 2026–2035. By product, monoclonal antibodies held a 45% share in 2025, with antisense and RNAi drugs expected to experience the highest CAGR over 2026–2035. By disease category, oncology held a leading share, while autoimmune diseases are expected to register the highest CAGR through 2026–2035. Contract manufacturing dominated by manufacturing type, while in-house manufacturing is anticipated to register the highest growth rate until 2026–2035. North America led the global market in 2025 with a revenue share of about 45%, and Asia-Pacific is anticipated to have the fastest-growing market between 2026 and 2035.

In Japan, the cell and gene therapy market was valued at USD 814.2 million in 2025 and is estimated to reach USD 2,151.4 million by 2034, exhibiting a CAGR of 11.40% from 2026–2034. Japan's Act on the Safety of Regenerative Medicine introduced an accelerated approval pathway that lets promising cell and gene therapies reach patients earlier, with conditional approvals based on interim efficacy data as long as post-market surveillance continues. Government support includes direct funding through the Japan Agency for Medical Research and Development, and the Development Bank of Japan invested in 4BIO Ventures III LP, a biotech fund focused on early-stage cell and gene therapy ventures. With roughly 30% of the population aged 65 or older, Japan carries one of the heaviest chronic disease burdens among developed nations. CAR-T therapies for relapsed blood cancers and stem cell treatments for heart tissue repair are advancing through Japan's clinical pipeline. Bristol-Myers Squibb received manufacturing and marketing approval for Abecma, a BCMA-directed CAR-T immunotherapy targeting Japanese patients with relapsed or refractory multiple myeloma. The CiRA Foundation partnered with Terumo BCT to build an automated, clinically scalable workflow for iPS cell-derived therapies, and Synplogen, a Kobe University spinout, signed an MOU with Ginkgo Bioworks to accelerate global gene therapy platform services and DNA production from Japan. AI-driven target discovery, predictive patient matching, automated cell manufacturing, real-time safety monitoring, and gene editing optimization are reshaping the market.

The Japan biologic drug lifecycle management market was valued at approximately USD 4.61 billion in 2024 and is projected to reach USD 9.69 billion by 2033, registering a CAGR of 8.6%. Lifecycle management strategies, including formulation improvements, patent extensions, and new indications, are helping manufacturers maximize the value of existing biologic drugs. Monoclonal antibodies represent the leading product segment due to their extensive use in oncology and autoimmune disease treatments. The Tokyo metropolitan region and Kansai area dominate market activities, with Tokyo, Osaka, and Nagoya as key hubs; hospitals remain the largest end-user segment. The emergence of biosimilars in Japan contributes to segmental diversity, providing cost-effective alternatives while sustaining market growth for original biologics. In January 2025, the FDA approved a new biosimilar to Humira (adalimumab), expanding the competitive biosimilar landscape.